case_images: PMC8992450_01
case_images: Radiologic images and timeline of the patient's clinical course.
case_images: cdr-4-1019.fig.1.jpg
case_images: PMC8992450_01_cdr-4-1019.fig.1.jpg
case_images: fig1
case_images: The whole course of treatment and changes of tumor indicators during the treatment are shown in Figures 1 and 2.
case_images: The changes in the carcinoembryonic antigen (CEA) level during the patient's clinical course.
case_images: cdr-4-1019.fig.2.jpg
case_images: PMC8992450_01_cdr-4-1019.fig.2.jpg
case_images: fig2
case_images: The whole course of treatment and changes of tumor indicators during the treatment are shown in Figures 1 and 2.
case_images: The mutations detected at different timepoints available from tissue or liquid biopsies.
case_images: cdr-4-1019.fig.3.jpg
case_images: PMC8992450_01_cdr-4-1019.fig.3.jpg
case_images: fig3
case_images: The results show that there was no targetable mutation, including E19del, EGFR-T790M, and BRAFV600E [Figure 3]. At this time, she agreed to take ultrasound-guided percutaneous cutting needle biopsy, and E19del combined with EGFR-T790M mutation was identified by next-generation sequencing (NGS) targeting 168 genes [Figure 3]. T790M was detected [Figure 3]. Therefore, she began to receive osimertinib (80 mg q.d), dabrafenib (150 mg b.i.d), and trametinib (2 mg q.d) in April 2021.